Cargando…
LGG-46. Survival Of The Fittest? A Prognostic Evaluation of Paediatric Low-Grade Glioma (PLGG) Survivor Functional Outcomes
INTRODUCTION: Whilst most patients with PLGG will survive, varying morbidities derived from patient,tumour & treatment characteristics can afflict life-long disabling functional impairments. No PLGG studies have evaluated potential prognostic factors for important functional outcomes. METHODS: W...
Autores principales: | Green, Katherine, Dahl, Christine, Jorgensen, Mette, O'Hare, Patricia, Opocher, Enrico, Slater, Olga, Gains, Jenny, Chang, Yen-Ching, Aquilina, Kristian, Bowman, Richard, Oldridge, Bronwen, Jacques, Thomas S, Stone, Thomas, Gan, Hoong-Wei, Bluebond-Langner, Myra, Hargrave, Darren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165037/ http://dx.doi.org/10.1093/neuonc/noac079.358 |
Ejemplares similares
-
LGG-33. A 40-year cohort study of evolving hypothalamic dysfunction in 90 infants and young children (<3y) with optic pathway gliomas
por: Picariello, Stefania, et al.
Publicado: (2022) -
LGG-37. Long-term Outcome, Visual Morbidity and Prognostic Factors in Infants and Young Children with Optic Pathway Glioma from the Great Ormond Street Hospital (GOSH) LGG - Cohort
por: Picariello, Stefania, et al.
Publicado: (2022) -
LGG-18. EVEROLIMUS TREATMENT IN PEDIATRIC PATIENTS AFFECTED BY LOW-GRADE GLIOMAS (pLGG) NON-TSC, BRAF v600-WT
por: Cacchione, Antonella, et al.
Publicado: (2020) -
LGG-53. PNOC001 (NCT01734512): A PHASE II STUDY OF EVEROLIMUS FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMAS (pLGG)
por: Mueller, Sabine, et al.
Publicado: (2020) -
LGG-04. A PHASE II RE-TREATMENT STUDY OF SELUMETINIB FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (pLGG): A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY
por: Fangusaro, Jason, et al.
Publicado: (2020)